biote Corp. (NASDAQ:BTMD) Major Shareholder Purchases $1,421,480.62 in Stock

biote Corp. (NASDAQ:BTMD) major shareholder Guines Llc purchased 436,037 shares of biote stock in a transaction on Tuesday, May 6th. The shares were acquired at an average cost of $3.26 per share, for a total transaction of $1,421,480.62. Following the purchase, the insider now owns 4,611,071 shares in the company, valued at approximately $15,032,091.46. This trade represents a 10.44 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Guines Llc also recently made the following trade(s):

• On Wednesday, April 30th, Guines Llc bought 1,933 shares of biote stock. The stock was acquired at an average price of $3.30 per share, with a total value of $6,378.90.
• On Monday, April 21st, Guines Llc purchased 8,801 shares of biote stock. The stock was acquired at an average cost of $3.27 per share, for a total transaction of $28,779.27.
• On Thursday, April 17th, Guines Llc acquired 6,874 shares of biote stock. The shares were bought at an average cost of $3.29 per share, with a total value of $22,615.46.
• On Wednesday, April 9th, Guines Llc bought 13,532 shares of biote stock. The stock was bought at an average cost of $3.21 per share, for a total transaction of $43,437.72.
• On Monday, April 7th, Guines Llc purchased 43,378 shares of biote stock. The stock was bought at an average price of $3.15 per share, for a total transaction of $136,640.70.
• On Thursday, April 3rd, Guines Llc acquired 7,321 shares of biote stock. The shares were bought at an average cost of $3.24 per share, with a total value of $23,720.04.
• On Monday, March 31st, Guines Llc bought 106,000 shares of biote stock. The stock was purchased at an average price of $3.32 per share, for a total transaction of $351,920.00.
• On Monday, March 17th, Guines Llc purchased 100 shares of biote stock. The shares were purchased at an average price of $3.74 per share, with a total value of $374.00.
• On Thursday, March 13th, Guines Llc bought 750,000 shares of biote stock. The shares were purchased at an average price of $3.22 per share, with a total value of $2,415,000.00.

biote Trading Up 6.7 %

NASDAQ:BTMD opened at $3.99 on Friday. biote Corp. has a twelve month low of $3.04 and a twelve month high of $8.44. The firm has a market capitalization of $218.29 million, a price-to-earnings ratio of 15.35 and a beta of 1.17. The firm’s fifty day simple moving average is $3.61 and its 200 day simple moving average is $4.93.

biote (NASDAQ:BTMD) last posted its earnings results on Wednesday, May 7th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. The business had revenue of $48.99 million during the quarter, compared to analyst estimates of $47.25 million. biote had a negative return on equity of 32.41% and a net margin of 5.20%. On average, analysts predict that biote Corp. will post 0.75 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Craig Hallum cut their price target on shares of biote from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, March 13th.

Institutional Trading of biote

A number of hedge funds have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD acquired a new stake in biote during the 4th quarter valued at $67,000. Commonwealth Equity Services LLC purchased a new position in biote in the 4th quarter valued at about $68,000. Public Employees Retirement System of Ohio acquired a new stake in shares of biote during the fourth quarter valued at about $69,000. Intech Investment Management LLC purchased a new stake in shares of biote during the fourth quarter worth about $71,000. Finally, SG Americas Securities LLC purchased a new stake in shares of biote during the fourth quarter worth about $76,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.